The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
It has been well established that mutations in the tumor suppressor gene, p53, occur readily in a vast majority of cancer tumors, including ovarian cancer. Typically diagnosed in stages three or four, ovarian cancer is the fifth leading cause of death in women, despite accounting for only 2.5% of al...
Main Authors: | Bryce Wallis, Katherine Redd Bowman, Phong Lu, Carol S. Lim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/13/1/159 |
Similar Items
-
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer
by: Katherine Redd Bowman, et al.
Published: (2019-04-01) -
High-grade serous carcinoma of unknown primary origin associated with STIC clinically presented as isolated inguinal lymphadenopathy: a case report
by: Paola Giancontieri, et al.
Published: (2024-02-01) -
A new grading system “two-tier” in clasification of ovarian serous carcinoma and evaluation of P53 gene expression by immunohistochemical staining
by: Narges Izadi-Mood, et al.
Published: (2014-01-01) -
Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
by: Phong Lu, et al.
Published: (2019-05-01) -
The Role of p53 in Nanoparticle-Based Therapy for Cancer
by: Olga Szewczyk-Roszczenko, et al.
Published: (2023-12-01)